Abstract LB-186: Somatic Y641 mutations in EZH2 alter the balance of di- and tri-methylation of H3K27 in diffuse large B-cell lymphomas
Elsie Diaz(Johnson & Johnson (United States)), Caretha L. Creasy, Alan P. Graves(GlaxoSmithKline (United States)), Michael T. McCabe(GlaxoSmithKline (United States)), Melissa B. Pappalardi(GlaxoSmithKline (United States)), Peter J. Tummino(Intarcia Therapeutics (United States)), Anthony Della Pietra(GlaxoSmithKline (United Kingdom)), Kimberly N. Smitheman(GlaxoSmithKline (United States)), Ryan G. Kruger(Arysta LifeScience (France)), Yong Jiang(Boston University), Stephanie Chen(Rutgers, The State University of New Jersey), Martín Brandt(SINTEF), Benjamin Schwartz, Sharon Sweitzer(GlaxoSmithKline (United States))
Cited by 0
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848